The Top 5 Biosimilars Articles for the Week of July 8

The Center for Biosimilars® recaps the top stories for the week of July 8, 2019.
July 12, 2019


Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of July 8, 2019.

Number 5: An advocacy organization for patients with breast cancer said recently that it wants to provide education about the potential of biosimilars to reduce costs and provide more treatment options.

Number 4: Biocon is facing yet another setback after the FDA issued a new Form 483 for its insulin facility.

Number 3: New research shows a significant association between drug makers' payments to prescribers and Medicare spending on Humira and Cimzia in inflammatory bowel disease.

Number 2: A judge has vacated the Trump administration’s rule requiring the disclosure of wholesale acquisition costs for drugs in direct-to-consumer television advertising.

Number 1: Samsung Bioepis has gained an updated label for its biosimilar adalimumab, Imraldi, referencing Humira. The biosimilar is now approved for storage in nonrefrigerated conditions for up to 28 days. 

Finally, last week, our e-newsletter asked whether you think that regulating patent settlements would incentivize companies to create patent thickets.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit



Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.